Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A2TSL71
Tue, 10.10.2023
SYNLAB AG
EQS-Media / 10.10.2023 / 08:32 CET/CEST
SYNLAB International GmbH
Moosacher Straße 88
80809 Munich
Germany
Press Release
Munich, 10 October 2023
SYNLAB launches revolutionary bipolar disorder diagnostic test: myEDIT-B
SYNLAB’s myEDIT-B is the world’s first blood-based test for the differential diagnosis betwee [ … ]
Fri, 29.09.2023
SYNLAB AG
SYNLAB AG
Moosacher Str. 88
80809 Munich
Germany
Press Release
Munich, 29 September 2023
SYNLAB enters into investment agreement relating to a public acquisition offer by Cinven
Cinven to launch public acquisition offer to all shareholders at a price of €10.00 per SYNLAB share in cash
SYNLAB knows Cinven well as a supportive long-st [ … ]
Mon, 14.08.2023
SYNLAB AG
SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany
Press Release
Munich, 14 August 2023
SYNLAB agrees to sell its veterinary diagnostics business to Mars
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, has agreed to sell its veterinary diagnostics business (SYNLAB VET) to Mars Incorpora [ … ]
Wed, 09.08.2023
SYNLAB AG
SYNLAB AG
Moosacher Str. 88
80809 Munich
Germany
Press Release
Munich, 9 August 2023
SYNLAB AG: Continued strong performance in the second quarter of 2023
Robust H1 2023 performance with revenue of €1.4 billion
Strong underlying organic growth: 7.1% in H1 2023 (Q2 2023: 4.4%)
Adjusted EBITDA margin in H1 2023 at 16.9% (Q2 2023: 1 [ … ]
Mon, 17.07.2023
SYNLAB AG
Munich, 17 July 2023
SYNLAB plays key role in the largest ever multinational study on cholesterol
SYNLAB participates in largest ever multi-national study to determine variations in lipid profiles to improve understanding of cardiovascular risk in different countries
Significant differences in total cholesterol levels across 17 countries provid [ … ]
Mon, 17.07.2023
SYNLAB AG
Munich, 17 July 2023
SYNLAB plays key role in the largest ever multinational study on cholesterol
SYNLAB participates in largest ever multi-national study to determine variations in lipid profiles to improve understanding of cardiovascular risk in different countries
Significant differences in total cholesterol levels across 17 countries provid [ … ]
Wed, 28.06.2023
SYNLAB AG
SYNLAB invests in innovative Healthcare Centre in Florence, strengthening its position as leading diagnostic services provider in Italy
SYNLAB invests €8 million to build a new 4000m2 medical care centre within Florence’s Manifattura Tabacchi
The new centre will offer a wide range of routine diagnostics, specialty testing, and medical healthcar [ … ]
Wed, 28.06.2023
SYNLAB AG
SYNLAB invests in innovative Healthcare Centre in Florence, strengthening its position as leading diagnostic services provider in Italy
SYNLAB invests €8 million to build a new 4000m2 medical care centre within Florence’s Manifattura Tabacchi
The new centre will offer a wide range of routine diagnostics, specialty testing, and medical healthcar [ … ]
Tue, 27.06.2023
SYNLAB AG
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, today announced the sale of SYNLAB SUISSE SA to Sonic Healthcare (ASX:SHL; ADR:SKHHY), having received the required approvals of antitrust authorities.
“After a careful review of our activities in Switzerland and the developments in the diagnostics sector [ … ]
Tue, 27.06.2023
SYNLAB AG
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, today announced the sale of SYNLAB SUISSE SA to Sonic Healthcare (ASX:SHL; ADR:SKHHY), having received the required approvals of antitrust authorities.
“After a careful review of our activities in Switzerland and the developments in the diagnostics sector [ … ]